A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

@article{Sharma2010API,
  title={A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.},
  author={Sunil Sharma and Vivek Abhyankar and Russell E Burgess and Jeffrey R. Infante and Rachel Trowbridge and Jamal Christo Tarazi and Sungjin Kim and Michael A Tortorici and Y. Chen and R L Robles},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 2},
  pages={
          297-304
        }
}
BACKGROUND Axitinib and bevacizumab are targeted therapies against the vascular endothelial growth factor pathway. METHODS Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5). Safety and pharmacokinetics were assessed. RESULTS Thirty patients were enrolled (n = 16, 8, and 6 for cohorts 1-3, 4, and 5, respectively). Plasma… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status

  • Current oncology reports
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.

Sumanta K. Pal, Winston Vuong, +11 authors Jeremy O. Jones
  • Molecular cancer therapeutics
  • 2015
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 1 EXCERPT

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 1 EXCERPT

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 1 EXCERPT

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 1 EXCERPT